Roche announced that its fourth-generation HIV combination antigen-antibody assay, the Elecsys HIV combi PT assay, has received FDA PMA approval...
Novartis announced updated data from the Phase III COMBI-v study showing a significant overall survival benefit for patients with BRAF...
Novartis announced results from the landmark phase III COMBI-d and COMBI-v clinical trials, concluding that first-line treatment with Tafinlar (dabrafenib)...
Novartis announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive...
Novartis announced that the Phase III COMBI-i study evaluating the investigational immunotherapy PDR 001 (spartalizumab), in combination with the targeted therapies Tafinlar (dabrafenib) and Mekinist (trametinib), did not meet its primary endpoint of investigator-assessed progression-free survival.
Novartis announced a new data analysis of COMBI-AD, a phase III multi-center study evaluating Tafinlar (dabrafenib) in combination with Mekinist...
Novartis has announced data from the Phase III COMBI-v study demonstrating an overall survival (OS) and a progression-free survival benefit...
GlaxoSmithKline plc announced overall survival (OS) results from COMBI-d trial which demonstrate a statistically significant reduction in the risk of...